These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8941602)

  • 1. Magic mushrooms: hope for a 'cheap high' resulting in end-stage renal failure.
    Franz M; Regele H; Kirchmair M; Kletzmayr J; Sunder-Plassmann G; Hörl WH; Pohanka E
    Nephrol Dial Transplant; 1996 Nov; 11(11):2324-27. PubMed ID: 8941602
    [No Abstract]   [Full Text] [Related]  

  • 2. Unpredictable Behavior Under the Influence of "Magic Mushrooms": A Case Report and Review of the Literature.
    Honyiglo E; Franchi A; Cartiser N; Bottinelli C; Advenier AS; Bévalot F; Fanton L
    J Forensic Sci; 2019 Jul; 64(4):1266-1270. PubMed ID: 30548541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hallucinogenic mushrooms in Denmark].
    Holm JW; Ebbehøj NE; Fjeldberg IA
    Ugeskr Laeger; 1997 Aug; 159(34):5116-8. PubMed ID: 9297322
    [No Abstract]   [Full Text] [Related]  

  • 4. Ethnobotany of psilocybin mushrooms, especially Psilocybe cubensis.
    Badham ER
    J Ethnopharmacol; 1984 Apr; 10(2):249-54. PubMed ID: 6539409
    [No Abstract]   [Full Text] [Related]  

  • 5. The pharmacology of psilocybin.
    Passie T; Seifert J; Schneider U; Emrich HM
    Addict Biol; 2002 Oct; 7(4):357-64. PubMed ID: 14578010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Automutilation after consumption of hallucinogenic mushrooms].
    Attema-de Jonge ME; Portier CB; Franssen EJ
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2869-72. PubMed ID: 18257429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived harm, motivations for use and subjective experiences of recreational psychedelic 'magic' mushroom use.
    Roberts CA; Osborne-Miller I; Cole J; Gage SH; Christiansen P
    J Psychopharmacol; 2020 Sep; 34(9):999-1007. PubMed ID: 32674668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Psychoactive mushrooms - an update].
    Supprian T; Frey U; Supprian R; Rösler M; Wanke K
    Fortschr Neurol Psychiatr; 2001 Dec; 69(12):597-602. PubMed ID: 11753749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.
    Kopra EI; Ferris JA; Winstock AR; Young AH; Rucker JJ
    J Psychopharmacol; 2022 Aug; 36(8):965-973. PubMed ID: 35388724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent psychiatric symptoms after eating psilocybin mushrooms.
    Benjamin C
    Br Med J; 1979 May; 1(6174):1319-20. PubMed ID: 571748
    [No Abstract]   [Full Text] [Related]  

  • 12. [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
    Jastrzebski M; Bala A
    Psychiatr Pol; 2013; 47(6):1157-67. PubMed ID: 25007546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity.
    Hackl B; Todt H; Kubista H; Hilber K; Koenig X
    Int J Neuropsychopharmacol; 2022 Apr; 25(4):280-282. PubMed ID: 34871422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apical regional wall motion abnormalities reminiscent to Tako-Tsubo cardiomyopathy following consumption of psychoactive fungi.
    Nef HM; Möllmann H; Hilpert P; Krause N; Troidl C; Weber M; Rolf A; Dill T; Hamm C; Elsässer A
    Int J Cardiol; 2009 May; 134(1):e39-41. PubMed ID: 18378018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Consumption of psilocybin-containing hallucinogenic mushrooms by young people].
    Lassen JF; Lassen NF; Skov J
    Ugeskr Laeger; 1992 Sep; 154(39):2678-81. PubMed ID: 1413197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities.
    Stebelska K
    Ther Drug Monit; 2013 Aug; 35(4):420-42. PubMed ID: 23851905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
    Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1279-1295. PubMed ID: 27856683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
    Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1268-1278. PubMed ID: 27578767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liberty caps: recreational hallucinogenic mushrooms.
    Pollock SH
    Drug Alcohol Depend; 1976 Oct; 1(6):445-7. PubMed ID: 1035156
    [No Abstract]   [Full Text] [Related]  

  • 20. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
    Grob CS; Danforth AL; Chopra GS; Hagerty M; McKay CR; Halberstadt AL; Greer GR
    Arch Gen Psychiatry; 2011 Jan; 68(1):71-8. PubMed ID: 20819978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.